Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.78M Sell
3,637,886
-209,386
-5% -$204K 1.41% 17
2026
Q1
$2.6M Buy
3,847,272
+7,500
+0.2% +$6.15K 1.04% 21
2025
Q4
$3.49M Buy
3,839,772
+48,984
+1% +$47K 1.23% 21
2025
Q3
$3.38M Buy
3,790,788
+195,000
+5% +$284K 1.16% 25
2025
Q2
$7.77M Buy
3,595,788
+892,127
+33% +$3.23M 3.68% 12
2025
Q1
$13M Sell
2,703,661
-295,284
-10% -$1.68M 6.32% 4
2024
Q4
$19.3M Sell
2,998,945
-22,446
-0.7% -$109K 9.88% 2
2024
Q3
$12.1M Buy
3,021,391
+356,392
+13% +$1.48M 7.76% 2
2024
Q2
$8.55M Buy
2,664,999
+217,259
+9% +$737K 6.58% 2
2024
Q1
$8M Buy
2,447,740
+527,830
+27% +$1.91M 7.48% 1
2023
Q4
$9.62M Buy
+1,919,910
New +$5.11M 7.92% 2

Other funds holding MYO

Rosalind Advisors's MYO Position: Q2 2026 in Review

Rosalind Advisors reduced its Myomo (MYO) stake by 5.4% in Q2 2026, selling an estimated $204K and leaving 3,637,886 shares worth $3.78M. The position accounts for 1.41% of the portfolio, ranked #17.

Rosalind Advisors first reported a position in MYO in Q4 2023 and has held it in 11 quarters since. The position peaked at $19.3M in Q4 2024. 80 funds tracked by Wall St. Rank hold MYO as of Q2 2026.

  • Rosalind Advisors held 3,637,886 shares of Myomo worth $3.78M as of Q2 2026.
  • Rosalind Advisors sold 209,386 Myomo shares in Q2 2026, an estimated $204K.
  • Myomo made up 1.41% of Rosalind Advisors's portfolio in Q2 2026, its #17 holding.
  • Rosalind Advisors first reported a position in Myomo in Q4 2023 and has held it in 11 quarters since.
  • Rosalind Advisors's Myomo position peaked at $19.3M in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Myomo as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.